Listed

Enveric Biosciences, Inc.: Form 10-Q for the period ended Jun 30, 2020

Filed with the SEC on Aug 14, 2020 and accepted by EDGAR at Aug 14, 2020, 16:22 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-04-01 to 2020-06-30$8.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2020-01-01 to 2020-06-30$17.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-04-01 to 2020-06-30$6.4mus-gaap:CostOfRevenue
Cost of revenue6 months2020-01-01 to 2020-06-30$14.2mus-gaap:CostOfRevenue
Gross profit3 months2020-04-01 to 2020-06-30$1.8mus-gaap:GrossProfit
Gross profit6 months2020-01-01 to 2020-06-30$3.7mus-gaap:GrossProfit
Selling, general and administrative3 months2020-04-01 to 2020-06-30$2.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2020-01-01 to 2020-06-30$5.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-04-01 to 2020-06-30−$1.2mus-gaap:OperatingIncomeLoss
Operating income6 months2020-01-01 to 2020-06-30−$2.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-04-01 to 2020-06-30$372.3kus-gaap:InterestExpense
Interest expense6 months2020-01-01 to 2020-06-30$532.3kus-gaap:InterestExpense
Income tax3 months2020-04-01 to 2020-06-30$17.5kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2020-01-01 to 2020-06-30$39.4kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-04-01 to 2020-06-30−$1.6mus-gaap:NetIncomeLoss
Net income6 months2020-01-01 to 2020-06-30−$3.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-04-01 to 2020-06-30−$0.48us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2020-01-01 to 2020-06-30−$1.03us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-04-01 to 2020-06-30−$0.48us-gaap:EarningsPerShareBasic
Basic EPS6 months2020-01-01 to 2020-06-30−$1.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-04-01 to 2020-06-303,518,118 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2020-01-01 to 2020-06-303,482,286 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2020-01-01 to 2020-06-30−$2.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-06-30$2.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-06-30$10.3mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$27.5mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$12.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$14.6mus-gaap:Liabilities
Shareholders' equityAt period end2020-06-30$12.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-20-015855. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.